Clinical characteristics of samples passing genotype QC
| Sex | Age | %Predicted FEV1 | FEV1/FVC | Pack-years | |||
|---|---|---|---|---|---|---|---|
| Sample collection | n | Male, n (%) | Mean (SD) | Mean (SD) | Mean (SD) | Samples with data (n) | Mean (SD) |
| Discovery analyses airflow limitation cases (total n=3226, with pack-years n=2517) | |||||||
| GS:SFHS | 508 | 224 (44.1%) | 58.9 (8.94) | 64.84 (12.64) | 0.580 (0.108) | 482 | 29.32 (24.96) |
| British Regional Heart Study | 425 | 425 (100%) | 70.1 (5.46) | 59.41 (14.66) | 0.597 (0.084) | 0 | – |
| British Women's Heart and Health Study | 254 | 0 (0%) | 69.3 (5.46) | 64.26 (12.40) | 0.603 (0.074) | 203 | 28.1 (18.36) |
| UK COPD cohort* | 209 | 129 (61.7%) | 68.7 (8.11) | 37.94 (15.29) | 0.447 (0.119) | 199 | 50.07 (27.79 |
| Hertfordshire Cohort Study | 317 | 203 (64.0%) | 66.1 (2.79) | 62.89 (13.57) | 0.589 (0.101) | 312 | 32.25 (23.37) |
| COPDBEAT* | 87 | 62 (71.3%) | 67.6 (8.77) | 45.19 (16.24) | 0.480 (0.115) | 86 | 38.69 (21.24) |
| Nottingham COPD study* | 76 | 48 (63.2%) | 67.2 (8.97) | 50.29 (15.04) | 0.482 (0.111) | 74 | 49.02 (26.86) |
| Nottingham smokers | 125 | 78 (62.4%) | 63.1 (8.60) | 46.27 (17.65) | 0.503 (0.125) | 124 | 41.75 (20.61) |
| Gedling study | 33 | 26 (78.8%) | 69.0 (8.23) | 59.67 (16.81) | 0.593 (0.103) | 31 | 45.47 (33.40) |
| English Longitudinal Study of Aging | 166 | 75 (45.2%) | 66.0 (8.17) | 54.84 (17.24) | 0.526 (0.149) | 0 | – |
| EU COPD Gene Scan* | 277 | 155 (56.0%) | 67.0 (8.68) | 38.51 (14.74) | 0.467 (0.120) | 277 | 46.43 (20.56) |
| GoTARDIS Study* | 749 | 412 (55.0%) | 68.8 (8.97) | 52.16 (14.14) | 0.509 (0.110) | 729 | 43.26 (21.59) |
| Discovery analyses controls (total n=4784, with pack-years n=3889) | |||||||
| GS:SFHS | 961 | 552 (57.4%) | 54.5 (8.41) | 98.18 (10.92) | 0.783 (0.051) | 961 | 28.92 (16.86) |
| British 1958 Birth Cohort | 1429 | 888 (62.1%) | 44 (0) | 100.90 (13.46) | 0.809 (0.060) | 1046 | 14.74 (10.07) |
| Oxford Biobank | 1770 | 832 (47.0%) | 41.6 (5.77) | – | – | 1682 | 9.09 (9.34) |
| GoDARTS | 624 | 402 (64.4%) | 59.0 (10.75) | – | – | 200 | 35.46 (25.89) |
| UK Biobank Lung Exome Variant Evaluation samples (meta-analysis and replication) | |||||||
| Airflow limitation cases | 4231 | 2379 (56.2%) | 59.54 (6.86) | 61.76 (11.8) | 0.607 (0.076) | 4231 | 42.41 (21.10) |
| Controls | 8979 | 4260 (47.4%) | 56.19 (7.92) | 101.40 (8.1) | 0.773 (0.038) | 8979 | 30.43 (14.41) |
*Sample collection is COPD case cohort.
GS:SFHS, Generation Scotland: Scottish Family Health Study; GoTARDIS, Tayside Allergy and Respiratory Disease Information System; QC, quality control.